LONDON, Oct. 25, 2021 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, today announced that it has received European patent grant number EP 3 463 323 as acceptance for its European patent application No. 17 728640.8. The patent grants certain protections for oral dosage forms…

Source

Previous articleBeckley Psytech Announces First Cohort Dosed in Phase 1 Clinical Trial Assessing Safety and Tolerability of Intranasal 5-MeO-DMT
Next articleHAVN Life Announces Departure of Rick Brar as Director